Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
J&J's Q4 Earnings Beat, Stock Down on Tepid 2025 Sales Guidance
11:51am, Wednesday, 22'nd Jan 2025
JNJ beats estimates for fourth-quarter earnings and sales. Its sales guidance for 2025 falls short of expectations.
Leading Indicators Data in Focus
11:41am, Wednesday, 22'nd Jan 2025
Ahead of today's regular stock market trading session, pre-market futures are picking up where they left off Tuesday afternoon: higher. Continued optimism for a pro-growth Trump administration are sen
Johnson & Johnson slides as soft sales guidance casts shadow
10:31am, Wednesday, 22'nd Jan 2025
Johnson & Johnson shares faced pressure on Wednesday as soft sales guidance for the coming year cast a shadow over expectation-beating fourth-quarter profit. Adjusted net earnings of US$4.95 billion w
Compared to Estimates, Johnson & Johnson (JNJ) Q4 Earnings: A Look at Key Metrics
10:31am, Wednesday, 22'nd Jan 2025
The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Str
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible
Dow Earnings: Procter & Gamble, Johnson & Johnson
10:21am, Wednesday, 22'nd Jan 2025
Blue-chip earnings reports continue to roll in , with results from Procter & Gamble Co (NYSE:PG) and Johnson & Johnson (NYSE:JNJ) on tap.
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Shareholders to Inquire about Securities Investigation
10:00am, Wednesday, 22'nd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ
Trump Tariffs Take Shape, Stargate AI Project Ramps Up, JNJ & PG Beat
09:29am, Wednesday, 22'nd Jan 2025
Kevin Green joins Morning Movers to look at how President Trump's tariffs plan could impact several areas of the market, specifically currencies and copper. Then, the focus shifts to Trump's ambitious
J&J Tops Q4 Adjusted Earnings Estimates, But 2025 Sales Outlook Falls Short
08:45am, Wednesday, 22'nd Jan 2025
Johnson & Johnson (JNJ) posted its fourth-quarter earnings report Wednesday morning, with adjusted profits beating expectations while the company's sales projections for the coming fiscal year fell sh
Johnson & Johnson Tops Q4 EPS Forecasts
08:44am, Wednesday, 22'nd Jan 2025
Pharmaceuticals and medical devices manufacturer Johnson & Johnson (JNJ 0.76%) reported fourth-quarter 2024 results on Wednesday, Jan. 22, that topped analyst consensus estimates. Revenue of $22.5 bil
Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates
08:31am, Wednesday, 22'nd Jan 2025
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago.
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
01:34am, Wednesday, 22'nd Jan 2025
Johnson & Johnson JNJ will release earnings results for its fourth quarter, before the opening bell on Wednesday, Jan. 22, 2025.
Q4 Earnings: 3 Consumer Staples Titans on Deck
09:06pm, Tuesday, 21'st Jan 2025
Among the bunch of companies expected to report in the coming days include a few consumer staples titans such as Procter & Gamble, Johnson & Johnson, and Kimberly-Clark.
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
03:41pm, Tuesday, 21'st Jan 2025
Johnson & Johnson JNJ will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects $2 in EPS and $22.44 billion in revenues as the company reports before market hours.
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
02:35pm, Tuesday, 21'st Jan 2025
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
